Tag

Rhythm Pharmaceuticals Inc.

1 article

Rhythm Pharma Phase‑2 PWS BMI Down 3%

Rhythm Pharmaceuticals disclosed Phase 2 setmelanotide data in 18 PWS patients, with 17 remaining on therapy at 52 weeks. Six‑month analysis (cut‑off May 7, 2026) showed mean BMI reduction of 3.06% ac